ibrutinib,rituximab
janssen,abbvie,biogen,roche
['ibru']
tivey et al nhs england interim covid19 measures enabled 1l use of #ibrutinib +/-r in #mcl in uk for past 2y data accumulating &amp; here is initial experience from a non-trial population. more evidence of biological heterogeneity affecting outcomes in btki-treated pts. #eha2022 
#Lymphoma #CLL specialist @OUHospitals
Hon. senior lecturer @UniofOxford
Low grade+elderly high grade UK NCRI grp member
UK #CLL forum exec committee 
#lymsm